Who are CSII followed by Lina's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/csii-followed-by-lina.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CSII followed by Lina — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CSII followed by Lina (CSII followed by Lina) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: insulin (basal-bolus) + GLP-1 receptor agonist. Area: Endocrinology / Diabetes.

marketed Combination therapy: insulin (basal-bolus) + GLP-1 receptor agonist Insulin receptor (CSII component); GLP-1 receptor (liraglutide component) Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

CSII followed by Lina (CSII followed by Lina) — Sun Yat-sen University. CSII (continuous subcutaneous insulin infusion) followed by liraglutide (Lina) provides basal-bolus insulin delivery combined with GLP-1 receptor agonism to improve glycemic control in diabetes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CSII followed by Lina TARGET	CSII followed by Lina	Sun Yat-sen University	marketed	Combination therapy: insulin (basal-bolus) + GLP-1 receptor agonist	Insulin receptor (CSII component); GLP-1 receptor (liraglutide component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: insulin (basal-bolus) + GLP-1 receptor agonist class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CSII followed by Lina — Competitive Intelligence Brief. https://druglandscape.com/ci/csii-followed-by-lina. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab